Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.
PLoS One
; 14(1): e0210593, 2019.
Article
em En
| MEDLINE
| ID: mdl-30608991
[This corrects the article DOI: 10.1371/journal.pone.0164646.].
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article